The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes

Meghana Kesireddy, Sarah A. Holstein

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Introduction: For patients with multiple myeloma who are eligible for high-dose melphalan therapy and autologous stem cell transplant (ASCT), the strategy of maintenance with low-dose lenalidomide therapy has become the current standard of care. However, this strategy is not curative, and many unanswered questions remain regarding the optimization of lenalidomide-based maintenance therapy. Areas covered: In this review, we evaluate the current data supporting the use of lenalidomide maintenance, either alone or in combination, following ASCT. We provide an overview of the management of lenalidomide-associated toxicities as well as address the unresolved topics of optimal treatment duration and use of minimal residual disease assessment. Expert opinion: While single-agent lenalidomide maintenance is a current standard of care, a one-size-fits-all approach to maintenance therapy is not optimal. The rapidly evolving landscape of multiple myeloma therapy in conjunction with ongoing clinical trials should enable a future where an individualized approach based on disease characteristics, response to induction and ASCT (or even non-ASCT consolidation approaches such as CAR T-cell therapy or bispecific antibodies), as well as patient preferences will influence the use of lenalidomide maintenance.

Original languageEnglish (US)
Pages (from-to)19-31
Number of pages13
JournalExpert Review of Clinical Pharmacology
Issue number1
StatePublished - 2022


  • Autologous stem cell transplant
  • lenalidomide
  • maintenance
  • multiple myeloma

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes'. Together they form a unique fingerprint.

Cite this